A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Clinical trial NCT03773666 · COMPLETED
Trial details
- NCT number
- NCT03773666
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-20
- Primary completion
- 2021-02-04
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.